Could The Most Effective Birth Control Soon Become The Cheapest?
The most effective reversible forms of birth control are mostly priced out of reach for millions of women who need it most—until now. An unusual partnership between a nonprofit pharmaceutical company and a traditional pharmaceutical distributor aims to increase access to IUDs (intrauterine devices) for U.S. servicewomen and in public clinics.
Liletta, a hormonal IUD approved by the FDA in April 2015, resulted from a joint venture between Allergan AGN +0.72% and Medicines360, a global nonprofit women’s health pharmaceutical company whose primary funding comes from an anonymous donor’s grant.
Liletta, a hormonal IUD approved by the FDA in April 2015, resulted from a joint venture between Allergan AGN +0.72% and Medicines360, a global nonprofit women’s health pharmaceutical company whose primary funding comes from an anonymous donor’s grant.